クローン病の主要市場、疾患管理、疫学、パイプライン評価、アンメットニーズ、2032年までの薬剤予測

主要8ヶ国市場全体のクローン病（CD）治療薬の売上は、2022年に約95億米ドルとなっています。同市場は、予測期間終了の2032年にかけてCAGR4.7%で拡大し、95億米ドルから150億米ドルに増加すると予測されています。市場成長の原動力となるのは、15のパイプライン、ジェネリック、バイオシミラー治療薬の承認と上市です。

当レポートでは、主要8ヶ国のクローン病市場について調査し、病気の概要と疫学、現在の治療法、アンメットニーズと機会、研究開発動向、地域別見通しなどをまとめています。

目次

第1章 クローン病：エグゼクティブサマリー

第2章 イントロダクション

第3章 病気の概要

• 病因学と病態生理学
  • 病因
  • 病態生理学
  • CDの分類

第4章 疫学

• 病気の背景
• 危険因子と併存疾患
• 世界的および歴史的動向
• 主要8ヶ国市場予測調査手法
• クローン病の疫学予測（2022年～2032年）
• 議論

第5章 疾病管理

• 診断と治療の概要
• 疾病管理に関するKOLの洞察

第6章 現在の治療選択肢

• 概要

第7章 アンメットニーズと機会の評価

• 概要
• 薬効、臨床反応、および持続的寛解の改善
• 治療に対する反応性と予後を予測するためのバイオマーカー
• 肛門周囲瘻孔の医学的管理の改善
• 最も効果的な治療法を決定するための臨床データ

第8章 研究開発戦略

• 概要
• 臨床試験の設計

第9章 パイプラインの評価

• 概要
• 臨床開発中の有望な薬剤

第10章 パイプラインの評価分析

• 概要
• 競争力評価

第11章 現在および将来の参入企業

• 概要
• 取引成立の動向

第12章 市場の展望

• 世界市場
• 米国
• EUヶ国
• 日本
• カナダ

第13章 付録

List of Tables

List of Tables

• Table 1: CD: Key metrics in the 8MM
• Table 2: Crohn's disease severities
• Table 3: Risk factors and comorbidities for CD
• Table 4: Treatment guidelines for CD
• Table 5: Top 10 deals by value, 2011-2022
• Table 6: CD market - global drivers and ba

List of Figures

List of Figures

• Figure 1: Global sales forecast by country for CD in 2022 and 2032
• Figure 2: Analysis of the company portfolio gap in CD during the forecast period
• Figure 3: Competitive assessment of the late-stage biologics benchmarked against Humira
• Fig

Abstract

This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan, Canada) and provides an Excel-based forecast model for Crohn's Disease market through 2032.

GlobalData estimates Crohn's Disease (CD) drug sales across the 8MM covered in this report will increase from $9.5 billion to $15.0 billion, at a compound annual growth rate (CAGR) of 4.7%, by the end of the forecast period in 2032. The growth of the market will be driven by the approval and launches of 15 pipeline, generic, and biosimilar therapies.

Major drivers of CD market growth over the forecast period are the -

• The emergence within the market of novel and innovative therapies that provides significant improvement in therapeutic efficacy over current treatments
• Successful legal rulings in favor of pharmaceutical companies over the legality of drug price legislature in the US
• Updated recommendations for the rapid incorporation of newer therapies by healthcare providers

Major barriers that will restrict the growth of the CD market during the forecast period are the -

• Legislature by the US government to reduce drug prices resulting in lower sales in the largest global market
• The emergence of several biosimilar and generic drugs entering the US market
• Disruption of the pharmaceutical supply chain and the production of biologics due to geopolitical events

Key Highlights

• GlobalData estimates that sales of drugs in the CD market was approximately $9.5 billion in 2022 in the 8MM. The global CD market is expected to grow to $15.0 billion in 2032, at a Compound Annual Growth Rate (CAGR) of 4.7%.

Major drivers of CD market growth over the forecast period are the -

• The emergence within the market of novel and innovative therapies that provides significant improvement in therapeutic efficacy over current treatments
• The launch of the MK-7240 companion diagnostic test
• Updated recommendations for the rapid incorporation of newer therapies by healthcare providers

Scope

• Overview of CD including epidemiology, disease etiology and management.
• Topline CD drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
• Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, Japan, and Canada over the 10-year forecast period.
• Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
• Analysis of the current and future market competition in the global CD therapeutics market. Insightful review of the key industry drivers and barriers.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the global CD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CD market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global CD therapeutics market from 2022-2032.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

• About GlobalData

1 Crohn's Disease: Executive Summary

• 1.1 Steady growth is expected for the CD market from 2022-32
• 1.2 Novel MOAs will provide market shifts throughout the forecast period
• 1.3 Lack of tools to properly treat patients with CD is a clear unmet need within the market
• 1.4 Pipeline Drugs
• 1.5 What Do Physicians Think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related reports
• 2.3 Upcoming reports

3 Disease Overview

• 3.1 Etiology and pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology
  • 3.1.3 CD Classification

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities
• 4.3 Global and historical trends
• 4.4 8MM forecast methodology
  • 4.4.1 Sources
  • 4.4.2 Forecast assumptions and methods
  • 4.4.3 Forecast assumptions and methods: diagnosed incident cases of CD
  • 4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of CD
  • 4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of CD by severity, diagnosed prevalent cases of fistulizing CD by severity, and diagnosed prevalent cases of CD in remission by severity
• 4.5 Epidemiological forecast for Crohn's disease (2022-32)
  • 4.5.1 Diagnosed incident cases of CD
  • 4.5.2 Age-specific diagnosed incident cases of CD
  • 4.5.3 Sex-specific diagnosed incident cases of CD
  • 4.5.4 Diagnosed prevalent cases of CD
  • 4.5.5 Age-specific diagnosed prevalent cases of CD
  • 4.5.6 Sex-specific diagnosed prevalent cases of CD
  • 4.5.7 Diagnosed prevalent cases of CD by severity
  • 4.5.8 Diagnosed prevalent cases of fistulizing CD by severity
  • 4.5.9 Diagnosed prevalent cases of CD in remission by severity
• 4.6 Discussion
  • 4.6.1 Epidemiological forecast insight
  • 4.6.2 COVID-19 impact
  • 4.6.3 Limitations of the analysis
  • 4.6.4 Strengths of the analysis

5 Disease Management

• 5.1 Diagnosis and treatment overview
• 5.2 KOL insights on disease management

6 Current Treatment Options

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Improved Drug Efficacy, Clinical Response, and Sustained Remission
• 7.3 Biomarkers to Predict Responsiveness to Therapy and Prognosis
• 7.4 Improved Medical Management of Perianal Fistulas
• 7.5 Clinical Data to Determine the Most Efficacious Therapy

8 R&D Strategies

• 8.1 Overview
  • 8.1.1 Novel MOAs
  • 8.1.2 Biomarkers
• 8.2 Clinical Trials Design
  • 8.2.1 Patient inclusion criteria
  • 8.2.2 Endpoints

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive Assessment

11 Current and Future Players

• 11.1 Overview
• 11.2 Deal-Making Trends

12 Market Outlook

• 12.1 Global Markets
  • 12.1.1 Forecast
  • 12.1.2 Drivers and barriers - global issues
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 5EU
  • 12.3.1 Forecast
  • 12.3.2 Key events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key Events
  • 12.4.3 Drivers and barriers
• 12.5 Canada
  • 12.5.1 Forecast
  • 12.5.2 Key events
  • 12.5.3 Drivers and barriers

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting Methodology
• 13.4 Primary Research - KOLs Interviewed for This Report
  • 13.4.1 KOLs
• 13.5 Primary Research - Prescriber Survey
• 13.6 About the Authors
  • 13.6.1 Analyst
  • 13.6.2 Managing Analyst
  • 13.6.3 Epidemiologist
  • 13.6.4 Reviewers
  • 13.6.5 Global Director of Therapy Analysis and Epidemiology